Deviceless Remote Patient Monitoring
Currently, RPM is limited to fee-for-service populations, and a narrow band of biometrics. Patients in the 'rising risk' category, as well as those under value-based contracts, are poorly served. Similarly, populations that struggle with behavioral health access, social determinants of health, and health equity are not able to longitudinally engage with their care providers in a sustainable (i.e. profitable) manner for the provider organizations.
CareSignal offers Deviceless Remote Patient Monitoring: scalable, accessible, health-equitable engagement programs that are condition-specific and clinically validated. More specifically, CareSignal offers over 30 different programs supporting conditions from COPD and CHF to opioid dependence and breastfeeding adherence. The programs function using SMS and phone call interactions, and are both automated and designed with patient common denominators in mind (more detail in 'differentiators' response). Clinically validated content, logic, scheduling algorithms, standard operating procedures, and alert thresholds allow CareSignal to guarantee outcomes and deliver scale and top-of-license work to provider-based care management teams serving value-based contracts across all types of patients.
1. Thirteen independent peer-reviewed journal publications have validated CareSignal's clinical, operational, and financial impact. Crucially, these outcomes (e.g. >2.0% reduction in A1c, >61% reduction in COPD hospitalizations, and >54% reduction in ESRD hospitalization admissions) have been replicated in hundreds of thousands of real-world patient implementations. 2. CareSignal AI: CareSignal predicts and prevents patients from disengaging using proprietary machine learning models (random survival forest, recurrent neural networks, and additional techniques). This yields a 6x better engagement than comparable solutions, with an engagement half-life of over one year including all causes of disengagement. 3. CareSignal will take risk on any contract signed. Because of the offering's extremely low COGS, combined with extremely high confidence in ability to deliver clinical and financial value in a short period of time (3 months to 12 months, depending on population), CareSignal offers risk-based pricing, standing shoulder to shoulder with our target market.
A large Medicare Advantage group, serving several thousand patients with CareSignal, showed a global reduction of 11% in claims for the cohort with CareSignal – this resulted in a $1.51M value per 1,000 patients per year, over thousands of patients and multiple years. This outcome was published as cover story of the American Medical Group Association's Group Practice Journal feature in early 2021. Full article: https://my.amga.org/store/s/product-details?id=a1B2E000007tFyw (email firstname.lastname@example.org for PDF). We have presented similar outcomes across multiple clients at AMA, ATA, and ACMA conferences, representing tens of thousands of patients' claims analyses. One CIO described her CareSignal implementation as "the best technology implementation I have ever experienced in 25 years in healthcare." We're not messing around.
Forget the flashy tech. Forget the trends of today that don't follow through. We started by iteratively designing our product with thousands of patients across multiple IRBs. And now we serve more than 23,000 patients on any given day nationally, and are adding over 800 patients per week. VBC FTW :)